Benefit-risk balance for marketed drugs : evaluating safety signals : report of CIOMS Working Group IV.
Material type: TextPublication details: Geneva : CIOMS, 1998. Description: 160 pISBN: 9290360682Subject(s): Drug evaluation | Risk assessment -- methods -- standards | Safety management | Decision support techniques | Adverse drug reaction reporting systems -- standards | Case-control studies | Models, Theoretical | Pharmaceuticals and BiologicalsNLM classification: WB 330 98COItem type | Current library | Call number | Copy number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Books | WHO HQ READING-RM | WB 330 98CO (Browse shelf(Opens below)) | 1 | Available | 00061149 | |
Books | WHO HQ BORROWABLE-COLL-STACKS | WB 330 98CO (Browse shelf(Opens below)) | 2 | Available | 00061150 |
Browsing WHO HQ shelves, Shelving location: READING-RM Close shelf browser (Hides shelf browser)
No cover image available | ||||||||
WB 330 89NO Non-specific aspects of treatment / | WB 330 93HO How to investigate drug use in health facilities : | WB 330 94CI Drug surveillance : | WB 330 98CO Benefit-risk balance for marketed drugs : | WB 354 2010WH RUS WHO best practices for injections and related procedures toolkit. | WB 356 2004WO External quality assessment for blood transfusion laboratory practice : | WB 356 2007ST Status of blood safety in WHO African Region: |
DC.CIOMS
eng.
WHODOC
WHO monograph
4
There are no comments on this title.